MCET (MultiCell Technologies) Beneish M-Score: 0.00 (As of Jul. 09, 2026)


What is MultiCell Technologies Beneish M-Score?

MultiCell Technologies MCET -90.00% Beneish M-Score is 0.00 as of Jul. 09, 2026.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for MultiCell Technologies's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of MultiCell Technologies was 0.00. The lowest was 0.00. And the median was 0.00.

MultiCell Technologies Beneish M-Score Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Beneish M-Score Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.52 -8.66 -16.37 -16.37 0.00

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MCET vs ERGO, OPLI, GLAG: Beneish M-Score Comparison

For the Biotechnology subindustry, MultiCell Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Beneish M-Score falls into.


MultiCell Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of MultiCell Technologies for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Aug15) TTM:Last Year (Aug14) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.195 + 0.586 + 0.012 + 0.012 = $0.81 Mil.
Gross Profit was 0.046 + 0.586 + 0.012 + 0.012 = $0.66 Mil.
Total Current Assets was $0.30 Mil.
Total Assets was $0.30 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.91 Mil.
Total Current Liabilities was $1.54 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -0.159 + 0.171 + -0.262 + -0.003 = $-0.25 Mil.
Non Operating Income was 0.006 + -0.006 + 0.009 + 0.22 = $0.23 Mil.
Cash Flow from Operations was -0.079 + 0.307 + -0.126 + -0.299 = $-0.20 Mil.
 Total Receivables was $0.00 Mil.
Revenue was 0.012 + 0.012 + 0.012 + 0.012 = $0.05 Mil.
Gross Profit was 0.012 + 0.012 + 0.012 + 0.012 = $0.05 Mil.
Total Current Assets was $0.14 Mil.
Total Assets was $0.14 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.71 Mil.
Total Current Liabilities was $1.30 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.805) / (0 / 0.048)
=0 / 0
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.048 / 0.048) / (0.656 / 0.805)
=1 / 0.814907
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.295 + 0.001) / 0.296) / (1 - (0.144 + 0) / 0.144)
=0 / 0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.805 / 0.048
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 0)) / (0 / (0 + 0.001))
= / 0
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.912 / 0.805) / (0.712 / 0.048)
=1.132919 / 14.833333
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 1.537) / 0.296) / ((0.038 + 1.297) / 0.144)
=5.192568 / 9.270833
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.253 - 0.229 - -0.197) / 0.296
=-0.962838

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
MultiCell Technologies (MCET) has a Beneish M-Score of 0.00 as of Jul. 09, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' Beneish M-Score too high?
MultiCell Technologies' current Beneish M-Score is 0.00.
How does MultiCell Technologies' Beneish M-Score compare to ERGO and OPLI?
MultiCell Technologies' Beneish M-Score of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Beneish M-Score is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.